Abstract：
OBJECTIVE: To investigate the serum lipid profiles of patients with localized osteosarcoma around the knee joint before and after neoadjuvant chemotherapy.
METHODS: After retrospectively screening the data of 742 patients between January 2007 and July 2020, 50 patients aged 13 to 39 years with Enneking stage II disease were included in the study. Serum lipid levels, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein-α [Lp(a)], and apolipoprotein A1, B, and E (ApoA1, ApoB, and ApoE), and clinicopathological characteristics were collected before and after neoadjuvant chemotherapy.
RESULTS: The mean levels of TC, TG, and ApoB were significantly increased following neoadjuvant chemotherapy (16%, 38%, and 20%, respectively, vs. pretreatment values; P<0.01). The mean levels of LDL-C and ApoE were also 19% and 16% higher, respectively (P<0.05). No correlation was found between the pretreatment lipid profile and the histologic response to chemotherapy. An increase in Lp(a) was strongly correlated with the Ki-67 index (R=0.31, P=0.023). Moreover, a trend toward longer disease-free survival (DFS) was observed in patients with decreased TG and increased LDL-C following chemotherapy, although this difference was not statistically significant (P=0.23 and P=0.24, respectively).
CONCLUSIONS: Significant elevations in serum lipids were observed after neoadjuvant chemotherapy in patients with localized osteosarcoma. There was no prognostic significance of pretreatment serum lipid levels on histologic response to neoadjuvant chemotherapy. The scale of increase in serum Lp(a) might have a potential prognostic role in osteosarcoma. Patients with increased LDL-C or reduced TG after chemotherapy seem to exhibit a trend toward favorable DFS.
METHODS: After retrospectively screening the data of 742 patients between January 2007 and July 2020, 50 patients aged 13 to 39 years with Enneking stage II disease were included in the study. Serum lipid levels, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein-α [Lp(a)], and apolipoprotein A1, B, and E (ApoA1, ApoB, and ApoE), and clinicopathological characteristics were collected before and after neoadjuvant chemotherapy.
RESULTS: The mean levels of TC, TG, and ApoB were significantly increased following neoadjuvant chemotherapy (16%, 38%, and 20%, respectively, vs. pretreatment values; P<0.01). The mean levels of LDL-C and ApoE were also 19% and 16% higher, respectively (P<0.05). No correlation was found between the pretreatment lipid profile and the histologic response to chemotherapy. An increase in Lp(a) was strongly correlated with the Ki-67 index (R=0.31, P=0.023). Moreover, a trend toward longer disease-free survival (DFS) was observed in patients with decreased TG and increased LDL-C following chemotherapy, although this difference was not statistically significant (P=0.23 and P=0.24, respectively).
CONCLUSIONS: Significant elevations in serum lipids were observed after neoadjuvant chemotherapy in patients with localized osteosarcoma. There was no prognostic significance of pretreatment serum lipid levels on histologic response to neoadjuvant chemotherapy. The scale of increase in serum Lp(a) might have a potential prognostic role in osteosarcoma. Patients with increased LDL-C or reduced TG after chemotherapy seem to exhibit a trend toward favorable DFS.
摘要：
目的：探讨膝关节周围局限性骨肉瘤患者新辅助化疗前后的血脂变化。
方法：在对2007年1月至2020年7月期间742例患者的数据进行回顾性筛选后，纳入了50例年龄在13至39岁的EnnekingII期疾病患者。血清脂质水平，包括总胆固醇（TC），甘油三酯（TG），高密度脂蛋白胆固醇（HDL-C），低密度脂蛋白胆固醇（LDL-C），脂蛋白-α[Lp(a)]，和载脂蛋白A1,B,和E（ApoA1，ApoB，和ApoE），收集新辅助化疗前后的临床病理特征。
结果：TC的平均水平，TG,和ApoB在新辅助化疗后显著增加(16%，38%,20%,分别,vs.预处理值；P<0.01)。LDL-C和ApoE的平均水平也分别高出19%和16%，分别为(P<0.05)。在治疗前的脂质分布和对化疗的组织学反应之间没有发现相关性。Lp（a）的增加与Ki-67指数密切相关（R=0.31，P=0.023）。此外，在化疗后TG降低和LDL-C升高的患者中观察到无病生存期（DFS）更长的趋势，尽管这种差异没有统计学意义（分别为P=0.23和P=0.24）。
结论：局部骨肉瘤患者新辅助化疗后血脂显著升高。治疗前血脂水平对新辅助化疗的组织学反应无预后意义。血清Lp（a）的升高可能在骨肉瘤中具有潜在的预后作用。化疗后LDL-C升高或TG降低的患者似乎表现出有利的DFS趋势。
方法：在对2007年1月至2020年7月期间742例患者的数据进行回顾性筛选后，纳入了50例年龄在13至39岁的EnnekingII期疾病患者。血清脂质水平，包括总胆固醇（TC），甘油三酯（TG），高密度脂蛋白胆固醇（HDL-C），低密度脂蛋白胆固醇（LDL-C），脂蛋白-α[Lp(a)]，和载脂蛋白A1,B,和E（ApoA1，ApoB，和ApoE），收集新辅助化疗前后的临床病理特征。
结果：TC的平均水平，TG,和ApoB在新辅助化疗后显著增加(16%，38%,20%,分别,vs.预处理值；P<0.01)。LDL-C和ApoE的平均水平也分别高出19%和16%，分别为(P<0.05)。在治疗前的脂质分布和对化疗的组织学反应之间没有发现相关性。Lp（a）的增加与Ki-67指数密切相关（R=0.31，P=0.023）。此外，在化疗后TG降低和LDL-C升高的患者中观察到无病生存期（DFS）更长的趋势，尽管这种差异没有统计学意义（分别为P=0.23和P=0.24）。
结论：局部骨肉瘤患者新辅助化疗后血脂显著升高。治疗前血脂水平对新辅助化疗的组织学反应无预后意义。血清Lp（a）的升高可能在骨肉瘤中具有潜在的预后作用。化疗后LDL-C升高或TG降低的患者似乎表现出有利的DFS趋势。
